Halozyme Therapeutics (HALO) Falls Short of Q4 Views
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $74.96 +3.19%
Revenue Growth %: +23.1%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +23.1%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (Nasdaq: HALO) reported Q4 loss of $0.17, $0.05 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $5.33 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
- BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
- McCormick & Co. (MKC) Tops Q2 EPS by 10c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
